Michael O. Falster
Sydney, NSW, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 71 publications
Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes.
Journal: Diabetes, obesity & metabolism
Published: May 19, 2026
Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025.
Journal: British journal of clinical pharmacology
Published: April 17, 2026
Cardiovascular Medicine Use Among Adults With ADHD: A Nationwide Study in Australia.
Journal: Journal of attention disorders
Published: March 28, 2026
Addressing missing data in real-world administrative health datasets.
Journal: European journal of cardiovascular nursing
Published: January 11, 2026
Patterns of follow-up testing of abnormal eGFR and UACR for the detection of chronic kidney disease in Australian primary care: analysis of a national general practice dataset.
Journal: BMJ open
Published: October 15, 2025
Uptake and Costs of the 60-Day Dispensing Policy for Antihypertensive Medicines in Australia: A Mixed Methods Study.
Journal: The Medical journal of Australia
Published: October 10, 2025
Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset.
Journal: Diabetes, obesity & metabolism
Published: April 29, 2025
Trends in use of sodium-glucose cotransporter 2 inhibitors among people with type 2 diabetes following hospitalisation with heart failure: A population-based study.
Journal: Diabetes research and clinical practice
Published: March 24, 2025
Reduced Use of Maintenance Therapies Among People With Cystic Fibrosis Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Australia.
Journal: Clinical therapeutics
Published: March 20, 2025
Variation in uptake of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor analogues in adults with type 2 diabetes at high cardiovascular risk.
Journal: European journal of clinical pharmacology
Published: March 20, 2025
Is the burden of diabetes in Australia underestimated? Comparison of diabetes ascertainment using linked administrative health data and an Australian diabetes registry.
Journal: Diabetes research and clinical practice
Published: December 17, 2024
Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?
Journal: Diabetes, obesity & metabolism
Published: October 02, 2024
Last Updated: 09/26/2026